Cytokinetics Inc vs NIO Inc. — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while NIO Inc. trades at $4.55 (market cap $11.59B). The key difference: Cytokinetics Inc and NIO Inc. are close in size by market cap, and Cytokinetics Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| CYTK | NIO | |
|---|---|---|
Market Cap | $10.63B | $11.59B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $7.89 |
52-Week Low | $34.31 | $4.44 |
Enterprise Value | $10.74B | $10.82B |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
NIO's stock trades at $4.555, down 5.5% in the last session amid a bearish technical signal and negative cash flow trends. The company shows revenue growth with 2025 sales reaching $87.49 billion, but remains unprofitable with a net loss of $15.57 billion. Recent news highlights delivery growth and policy support for EVs in China, yet investor sentiment is mixed due to competitive pressures and high cash burn.
The outlook is cautious; while analyst consensus leans bullish with 54% buy ratings, fundamental weaknesses in profitability and negative equity pose significant risks. Upside depends on sustained revenue expansion and cost control, but volatility from market sentiment and execution challenges warrants careful monitoring for investors.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →